TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02244866
Drug: Pergoveris (FSH and LH)
Normalized name: follicle stimulating hormone
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Study: NCT02244866
Drug: Follitropin alpha (FSH)
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Study: NCT00937924
Drug: Meperidine, Midazolam
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00937924
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00937924
Drug: Promethazine
Normalized name: Promethazine
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02362490
Drug: peginterferon alpha 2a
Normalized name: peginterferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
Study: NCT03435133
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg oral bolus plus oral 10 mg once daily
Study: NCT03435133
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mg oral bolus plus oral 90 mg every 12 hours daily
Study: NCT02964936
Drug: roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT03526250
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01715805
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine capsules 1.5 to 4.5 mg/day
Study: NCT03322865
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity
Study: NCT04479813
Drug: Moxonidine 0.2 MG
Normalized name: moxonidine 0.2 MG
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Study: NCT03315000
Drug: Vilanterol and Fluticasone Furoate
Normalized name: vilanterol and fluticasone furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Same as vilanterol arm description
Study: NCT03315000
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Same as fluticasone arm description
Study: NCT01049425
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 cycles, intravenous use, day 1 every three weeks
Study: NCT01049425
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
Study: NCT01049425
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles, intravenous infusion, day one every three weeks
Study: NCT01792063
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03101735
Drug: Dimethyl Fumarate (DMF)
Normalized name: Dimethyl sulfone
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
Study: NCT00872144
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
Study: NCT02224729
Drug: Bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02224729
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT02224729
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01306162
Drug: Dabigatran etexilate plus dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
Study: NCT01306162
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg as single dose
Study: NCT01306162
Drug: Dabigatran etexilate plus dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
Study: NCT01306162
Drug: Dabigatran etexilate plus dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
Study: NCT01306162
Drug: Dabigatran etexilate plus dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
Study: NCT01556438
Drug: Bortezomib IV
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT01556438
Drug: Bortezomib SC
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT01556438
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT00659633
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
Study: NCT01703364
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days
Study: NCT04423068
Drug: Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet
Study: NCT00854451
Drug: omeprazole plus amoxicillin
Normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00126971
Drug: chlorproguanil-dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00095264
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00137033
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02741960
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg metformin three times daily
Study: NCT00384228
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01360151
Drug: ranibizumab(Lucentis), verteporfin(Visudyne)
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
Study: NCT04575467
Drug: CBL-514
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 will be administered via injection into the subcutaneous adipose layer.
Study: NCT03007927
Drug: Bupivacaine-Dexamethasone
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
Study: NCT03007927
Drug: Bupivacaine- physiological solution
Normalized name: bupivacaine Injectable Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 1,5 mg/kg- physiological solution
Study: NCT03332524
Drug: capsule Chlorpheniramine 4mg and 1 Placebo
Normalized name: PLACEBO CAP/TAB
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 4mg and one capsule Placebo 3/72days
Study: NCT03346629
Drug: Mifepristone + Misoprostol
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
Study: NCT03104634
Drug: Aclidinium bromide/formoterol fumarate dihydrate
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over design with washout interval. Randomized order of active and placebo arm
Study: NCT01558622
Drug: tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg intravenous infusion
Study: NCT01558622
Drug: pethidine hydrochloride
Normalized name: Pethidine hydrochloride
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg intravenous infusion
Study: NCT01558622
Drug: vitamin c
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg intravenous infusion
Study: NCT01994330
Drug: desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
Study: NCT01968239
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: comparison of different re-treatment criteria for intravitreal injection of ranibizumab
Study: NCT02039050
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039050
Drug: Aclidinium
Normalized name: Aclidinium
DrugBank: Aclidinium (DB08897)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00295750
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
Study: NCT00295750
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
Study: NCT00295750
Drug: Leuprolide 7.5 mg
Normalized name: leuprolide 7.5 mg/month intramuscular kit
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
Study: NCT03152552
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin was supplied as capsules taken orally.
Study: NCT00349089
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
Study: NCT00349089
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29
Study: NCT00349089
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
Study: NCT00733317
Drug: 0.5 mg/ml budesonide nebules
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
Study: NCT00733317
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will receive 2 ml of saline every 20 minutes for 3 times
Study: NCT00839072
Drug: Trazodone HCl
Normalized name: trazodone HCl
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg immediate-release tablet, dosing q8h
Study: NCT00839072
Drug: Trazodone HCl
Normalized name: trazodone HCl
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg extended-release caplet, single dose
Study: NCT00160433
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Tablet, oral Daily for 12 weeks
Study: NCT00160433
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg Tablet, oral Daily for 12 weeks
Study: NCT00160433
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg Tablet, oral Daily for 12 weeks
Study: NCT00758953
Drug: Danazol Once Weekly
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: semi-solid
Study: NCT00758953
Drug: Danazol Twice Weekly
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: semi-solid
Study: NCT02983734
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partial agonist of N-methyl-D-aspartate (NMDA) receptor
Study: NCT01965834
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
Study: NCT00158743
Drug: Anti-digoxin antibody (FAB fragment)
Normalized name: digoxin antibodies Fab fragments
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
Study: NCT03151434
Drug: US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
Study: NCT03151434
Drug: Thoracic Epidural (0.125% bupivicaine/hydromorphone)
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheter will be placed in the thoracic region prior to surgery.
Study: NCT02037347
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02096900
Drug: zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem will be given one time at 0.25 mg/kg pre-operatively
Study: NCT02096900
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02920905
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds.
Study: NCT02920905
Drug: atracurium
Normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds.
Study: NCT02920905
Drug: Mg sulphate
Normalized name: MG 217 Psoriasis
DrugBank: Glyceryl 1-oleate (DB13171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds.
Study: NCT03216876
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
Study: NCT03829904
Drug: Placebo (Corn starch pill manufactured to mimic VGH-BPH1)
Normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch pill manufactured to mimic VGH-BPH1
Study: NCT01432119
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
Study: NCT01432119
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
Study: NCT00048516
Drug: paricalcitol capsule
Normalized name: Paricalcitol Capsules
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02283866
Drug: Administering desflurane according to the patient's BIS value
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administering desflurane according to the patient's BIS value
Study: NCT02283866
Drug: Administering desflurane at 1 MAC
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administering desflurane at 1 MAC
Study: NCT03034577
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
Study: NCT03034577
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.